6CM
KYNB

683 Capital Management’s Kyntra Bio KYNB Stock Holding History

683 Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-85,536
Closed -$1.13M – 182
2024
Q4 		$1.13M Hold
85,536
– – 0.07% 106
2024
Q3 		$854K Sell
85,536
-464
-0.5% -$7K 0.07% 105
2024
Q2 		$1.92M Buy
86,000
+12,000
+16% +$371K 0.15% 91
2024
Q1 		$4.35M Buy
74,000
+45,990
+164% +$1.98M 0.32% 61
2023
Q4 		$621K Buy
+28,010
New +$423K 0.05% 95

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

683 Capital Management's KYNB Position: Q1 2025 in Review

683 Capital Management sold out of Kyntra Bio (KYNB) in Q1 2025, closing a stake of 85,536 shares — an estimated $1.13M sold.

683 Capital Management first reported a position in KYNB in Q4 2023 and held it in 5 quarters. The position peaked at $4.35M in Q1 2024. 54 funds tracked by Wall St. Rank hold KYNB as of Q1 2025.

  • 683 Capital Management reported no remaining Kyntra Bio position as of Q1 2025 after selling out during the quarter.
  • 683 Capital Management sold 85,536 Kyntra Bio shares in Q1 2025, an estimated $1.13M.
  • 683 Capital Management first reported a position in Kyntra Bio in Q4 2023 and held it in 5 quarters.
  • 683 Capital Management's Kyntra Bio position peaked at $4.35M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.